NCT06501144已完成不适用
Real-world Longitudinal Follow-up Study of a Digital Health Application in Erectile Dysfunction
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 317
- 试验地点
- 1
- 主要终点
- Assessment of the real-world longitudinal effect of the intervention
研究概览
简要总结
The goal of this observational study is to assess the long-term effectiveness of a digital health application for treating erectile dysfunction in men aged 18 and older. The main questions it aims to answer are:
- Will participants maintain an improvement of their erectile function, that means maintain an improvement of at least 3 points in the IIEF-5 score at 3 months post-therapy?
- How does the application affect overall health status and disease-related quality of life?
Participants will:
- Complete validated questionnaires (IIEF-5, PGI-I, QOL-Med) to track erectile function, overall health status, and quality of life at up to two follow-up points after using the app with a 3-month self-management program combining cardiovascular training, pelvic floor exercises, psychological support, and educational content.
- Provide information on demographics, risk factors, and other relevant health characteristics for subgroup analysis.
详细描述
The intervention that needs to be completed prior participation in this study involves a digital therapy program delivered via a smartphone or tablet application. This program includes several components aimed at addressing different aspects for the treatment of erectile dysfunction:
- Pelvic Floor Exercises
- Cardiovascular Exercises
- Physiotherapeutic Exercises
- Mental or sexual therapeutic Exercises
- Educational Content
Overall, the digital therapy program is designed to provide comprehensive support for men with erectile dysfuntion, addressing both physical and psychological aspects of the condition to improve symptom severity, quality of life, and patient activation.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Men with erectile dysfunction of organic origin (ICD 10 code N48.4) and IIEF-5 score < 21 as determined at therapy start with Kranus EDERA
- •Completion of the 12-week app-based therapy with Kranus EDERA
- •Improvement in the IIEF-5 score of ≥ 3 points after completion of the Kranus EDERA therapy compared to the score at the start of the therapy
- •Age over 18
排除标准
- •Failure to provide informed consent
- •Started a new therapy with Kranus EDERA between the end of the last therapy cycle and patient survey
- •Started PDE-5 inhibitor treatment during the Kranus EDERA therapy or between the end of the last therapy cycle and patient survey
- •Underwent prostatectomy (removal of the prostate gland), radiation or seeds of the prostate gland during the Kranus EDERA therapy or between the end of the last therapy cycle and patient survey
- •Performed auto-injection therapy (SKAT, MUSE) during the Kranus EDERA therapy or between the end of the last therapy cycle and patient survey
- •Obtained a penile implant during the Kranus EDERA therapy or between the end of the last therapy cycle and patient survey
- •Underwent major surgery in the small pelvis with probable impairment of the neurovascular supply (e.g., rectum resection, urinary bladder removal) during the Kranus EDERA therapy or between the end of the last therapy cycle and patient survey
- •Nervous diseases (e.g., multiple sclerosis (MS), Parkinson's disease, stroke, dementia, psychiatric diseases) acquired during the Kranus EDERA therapy or between the end of the last therapy cycle and patient survey
- •Developed pronounced circulatory disorders (peripheral arterial occlusive disease) during the Kranus EDERA therapy or between the end of the last therapy cycle and patient survey
- •Trauma involving the pelvis/penis/spine during the Kranus EDERA therapy or between the end of the last therapy cycle and patient survey
- •Any other newly developed diseases potentially affecting erectile function (e.g., leading to a longer period of hospitalization) during the Kranus EDERA therapy or between the end of the therapy cycle and patient survey
结局指标
主要结局
Assessment of the real-world longitudinal effect of the intervention
时间窗: 6 months after start of the app-based therapy
The primary endpoint is the rate of patients maintaining an IIEF-5 score improvement of ≥ 3 points compared to baseline (start of app-based therapy) after the app-based therapy
次要结局
- Assessment of the real-world effect of the intervention on overall improvement of patients' health status(6 months after start of the app-based therapy)
- Assessment of the real-world effect of the intervention on disease-related quality of life(6 months after start of the app-based therapy)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
Unknown
Digital-powered healthcare: Optimising communication, engagement and treatment compliance in patients with implant-related infectionsTrauma related infectionOrthopaedic implant related infectionSurgery - Other surgeryInfection - Studies of infection and infectious agentsACTRN12623000546651Metro North Health48
尚未招募
不适用
Study of RE.DOCTOR Vitals® Software AccuracyCardiovascular DiseasesPre-DiabetesPrimary CareDiabetesRespiratory DisorderNCT06237322RE.DOCTOR LLC1,000
进行中（未招募）
不适用
Prospective Longitudinal Multicentric Study to Evaluate Syde® Digital Endpoints in Healthy AdultsHealthy AdultsNCT06679608SYSNAV129
进行中（未招募）
不适用
Assessment of the Health and Lifestyle ToolDiabetes Mellitus, Type 2NCT04624321Region Skane300
Unknown
不适用
An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCIDAdenosine Deaminase DeficiencySevere Combined Immunodeficiency (SCID)NCT04049084University of California, Los Angeles70